Phototherapy (PUVA / NB-UVB)

Sources and Guidelines Referenced

The clinical recommendations and evidence base in this guide are derived from published medical guidelines and peer-reviewed consensus statements. Key sources include: American Academy of Dermatology and National Psoriasis Foundation (AAD-NPF) Guidelines of Care for the Management and Treatment of Psoriasis with Phototherapy (Elmets et al., 2019); British Association of Dermatologists (BAD) Guidelines for Narrowband Ultraviolet B Phototherapy (Ling et al., 2016) and PUVA Photochemotherapy (Dawe et al., 2016); European Academy of Dermatology and Venereology (EADV) Consensus on Phototherapy (EuroGuiDerm 2021); and International Vitiligo Task Force Recommendations (Taieb et al., 2013).

Phototherapy (PUVA / NB-UVB): A Comprehensive Patient Guide

1. Definition and Medical Identity

Phototherapy is the therapeutic application of specific ultraviolet light wavelengths to treat inflammatory, autoimmune, and lymphoproliferative skin diseases. Primary modalities include narrowband ultraviolet B (NB-UVB) and photochemotherapy (PUVA), which combines a photosensitizing drug with ultraviolet A light. It is an established dermatological procedure designed to induce cutaneous immune tolerance and clear skin lesions.

In clinical dermatology, phototherapy is categorized as a targeted physical immunomodulatory therapy. The treatment uses controlled artificial light emitted by specialized medical lamps within reflective walk-in cabinets or localized delivery units. Unlike ambient sunlight, which contains broad-spectrum solar radiation including damaging shortwave ultraviolet C and infrared waves, medical phototherapy isolates precise wavelengths known to maximize therapeutic benefits while minimizing acute tissue damage.

Narrowband ultraviolet B (NB-UVB) utilizes a ultra-specific emission spectrum centered between 311 and 312 nanometers. This targeted band was isolated after photobiological research demonstrated that wavelengths around 311 nanometers yield optimal therapeutic clearance for plaque psoriasis and vitiligo with significantly less erythema (sunburn response) compared to traditional broadband ultraviolet B (BB-UVB, 280–320 nanometers).

Psoralen plus ultraviolet A (PUVA) is a form of photochemotherapy. It pairs a photosensitizing compound called psoralen (typically 8-methoxypsoralen or methoxsalen) with long-wave ultraviolet A radiation (UVA, 320–400 nanometers). Psoralens can be administered orally as capsules, dissolved in warm bathwater (bath PUVA), or applied topically as a lotion (topical PUVA). The psoralen molecules intercalate into cellular DNA, rendering skin cells hyper-sensitive to UVA radiation. When exposed to UVA light, the compound forms DNA adducts that inhibit abnormal cell division.

2. The Underlying Condition or Need

Phototherapy addresses disorders characterized by dysregulated cutaneous immune activity, rapid epidermal cell turnover, or localized autoimmune destruction of melanocytes. Conditions like psoriasis, vitiligo, and atopic dermatitis stem from complex immune signals where white blood cells hyperactivate, releasing pro-inflammatory cytokines that disrupt normal skin architecture.

In healthy skin, epidermal cells (keratinocytes) replicate in the basal layer, mature, and shed over approximately 28 to 30 days. In plaque psoriasis, an overactive immune cascade involving T-helper 17 (Th17) and T-helper 1 (Th1) lymphocytes accelerates this cycle to just 3 to 5 days. Keratinocytes accumulate rapidly on the skin surface, forming thick, scaly, erythematous plaques. Without intervention, extensive psoriasis can lead to skin barrier failure, secondary infections, functional impairment, severe itching, and joint complications via psoriatic arthritis.

In vitiligo, cytotoxic T-lymphocytes target and destroy melanocytes (pigment-producing cells) within the basal layer of the epidermis. This autoimmune attack leaves localized or widespread patches of depigmentation. Unmanaged vitiligo often progresses, leading to extensive skin color loss and pronounced psychological distress. According to international consensus guidelines from the Vitiligo Task Force (Taieb et al., 2013), early intervention with light therapy can halt active depigmentation and stimulate dormant stem cells in hair follicles to re-pigment the skin.

In atopic dermatitis (eczema), barrier dysfunction combined with immune dysregulation (predominantly T-helper 2 pathways) leads to intense pruritus, lichenification (skin thickening), and recurrent bacterial colonization. Left untreated, severe atopic dermatitis severely impairs sleep, compromises quality of life, and increases susceptibility to systemic infections. Phototherapy provides a non-systemic method to lower immune activity in the skin, restore bacterial balance, and break the itch-scratch cycle.

3. How the Treatment Works — Mechanism

Phototherapy works through precise cellular photobiological mechanisms, including induction of T-lymphocyte apoptosis, downregulation of pro-inflammatory cytokines, suppression of Langerhans cell antigen presentation, and activation of follicular melanocyte stem cells. Photons of light interact with target molecules in the skin to modify immune responses.

When NB-UVB light (311–312 nanometers) strikes the skin, photons are absorbed by cellular DNA, generating specific photoproducts such as cyclobutane pyrimidine dimers. This subtle, controlled DNA modification triggers tumor suppressor pathways (such as p53), inducing programmed cell death (apoptosis) in hyperactive pathogenic T-cells residing in the epidermis and papillary dermis. The reduction of infiltrating T-cells decreases localized concentrations of key inflammatory cytokines, including interleukin-17 (IL-17), interleukin-22 (IL-22), and interferon-gamma (IFN-γ).

Simultaneously, ultraviolet radiation affects antigen-presenting cells known as Langerhans cells. UV light depletes epidermal Langerhans cells and impairs their capacity to present antigens to naive T-lymphocytes, thereby blunting the localized autoimmune reaction. In conditions like vitiligo, NB-UVB radiation stimulates the proliferation and migration of melanocyte stem cells located in the outer root sheath of hair follicles. These cells migrate outward to the depigmented epidermis, synthesizing new melanin pigment visible as small repigmentation macules.

In PUVA photochemotherapy, oral or bath-administered methoxsalen enters the nuclei of cutaneous cells. Upon exposure to UVA wavelengths (320–400 nanometers), activated psoralen molecules bind covalently to pyrimidine bases in DNA, creating monofunctional adducts and interstrand cross-links. This cross-linking halts DNA transcription and cell division in rapidly proliferating keratinocytes and lymphocytes. Because UVA light possesses longer wavelengths than UVB, it penetrates deeper into the reticular dermis, making PUVA highly effective for thicker skin lesions, deep inflammatory infiltrates, and palmaplantar dermatoses.

4. Types and Variations

Dermatologists select specific phototherapy modalities based on disease diagnosis, severity, lesion distribution, skin phototype, and individual medical history. Modalities vary in wavelength, photosensitizer requirement, penetration depth, and delivery device.

The standard delivery system for generalized body involvement is the full-body walk-in cabinet. These units feature arrays of specialized 6-foot fluorescent bulbs arranged vertically. Integrated computerized controllers precisely monitor radiation output in real time using internal UV sensors, delivering exact dosages adjusted for bulb degradation. For localized disease—such as involvement restricted to hands, feet, or scalp—specialized hand/foot panel units or high-intensity fiber-optic comb attachments are used to prevent unnecessary light exposure to healthy skin.

Selecting the proper modality requires evaluating disease burden. According to AAD-NPF guidelines (Elmets et al., 2019), NB-UVB is the preferred initial light therapy for widespread psoriasis due to its high safety margin, lack of drug-related nausea, and lower long-term risk of skin cancer compared to PUVA. PUVA is typically reserved for cases that fail to respond to NB-UVB, patients with deep dermal lesions, or those with severe palmaplantar pustulosis.

5. Who the Treatment Is For — Indications

Phototherapy is indicated for adult and pediatric patients with moderate-to-severe inflammatory, autoimmune, or pruritic skin conditions affecting more than 10% of total body surface area (BSA), or localized disease causing significant functional impairment.

Clinical guidelines establish clear indications for phototherapy across several primary dermatological diagnoses:

• Plaque Psoriasis: Indicated for moderate-to-severe chronic plaque psoriasis involving >10% BSA, or localized disease refractory to topical corticosteroids. It is also used for gutate psoriasis, which often responds rapidly to NB-UVB.
• Vitiligo: Indicated for active or generalized non-segmental vitiligo. AAD guidelines highlight NB-UVB as the gold standard for stabilizing disease progression and stimulating follicular repigmentation.
• Atopic Dermatitis (Eczema): Prescribed for chronic, severe eczema unresponsive to optimal topical therapies and calcineurin inhibitors, helping reduce secondary bacterial colonization by Staphylococcus aureus.
• Cutaneous T-Cell Lymphoma (Mycosis Fungoides): Indicated for early-stage (Stage IA to IIA) cutaneous T-cell lymphoma, where superficial atypical T-cell clones can be cleared with NB-UVB or PUVA.
• Pruritic and Inflammatory Disorders: Effective for lichen planus, prurigo nodularis, pityriasis rubra pilaris, generalized granuloma annulare, and refractory uremic pruritus associated with end-stage renal disease.
• Photodermatoses (Desensitization): Used as a pre-season hardening strategy for severe polymorphous light eruption (PLE) to build cutaneous light tolerance before natural summer sunlight exposure.

Diagnostic workup before initiating phototherapy includes a thorough skin examination, determination of Fitzpatrick skin phototype (Types I through VI), evaluation of previous light exposure, and assessment of systemic medications for potential photosensitizing agents.

6. Who the Treatment Is NOT For — Contraindications

Phototherapy is contraindicated in patients with genetic disorders featuring severe DNA repair defects, active cutaneous malignancies, systemic autoimmune conditions exacerbated by sunlight, or those taking potent photosensitizing medications.

Contraindications are divided into absolute and relative categories to ensure patient safety:

Absolute Contraindications

• Xeroderma Pigmentosum: A genetic defect in nucleotide excision repair that leads to rapid skin cancer development upon light exposure.
• Cutaneous Malignancies: Active melanoma or non-melanoma skin cancers (squamous cell carcinoma or advanced basal cell carcinoma).
• Lupus Erythematosus: Systemic or cutaneous lupus erythematosus (e.g., subacute cutaneous lupus), where UV radiation triggers severe autoimmune flares and systemic disease activity.
• Genetic Photosensitivity Syndromes: Conditions such as Bloom syndrome, Cockayne syndrome, and Gorlin syndrome.

Relative Contraindications

• History of Non-Melanoma Skin Cancer: Prior history of multiple squamous cell carcinomas requires careful risk-benefit analysis, low-dose protocols, and strict skin surveillance.
• Concurrent Immunosuppressive Medication: Patients taking systemic cyclosporine or receiving organ transplants have an elevated risk of skin carcinogenesis when exposed to phototherapy, particularly PUVA.
• Dysplastic Nevus Syndrome: Presence of numerous atypical nevi requires thorough baseline mapping and ongoing mole checks.
• Cataracts or Aphakia: Relevant primarily for oral PUVA; patients lacking natural lenses or with significant cataracts require strict protective eyewear during and after treatment.
• Claustrophobia: Inability to tolerate enclosed standing light cabinets may require open panel units or targeted localized light devices.

7. Alternatives and Clinical Comparison

Dermatologists evaluate phototherapy alongside other treatments, including advanced topical agents, oral systemic immunomodulators, and biologic therapies. Treatment choice depends on disease extent, patient medical history, co-morbidities, and lifestyle factors.

Topical corticosteroids and calcineurin inhibitors remain first-line options for localized skin disease (<5% BSA). However, applying topicals over extensive body surface areas is impractical and risks systemic absorption, leading to hypothalamic-pituitary-adrenal (HPA) axis suppression or localized skin atrophy. Oral systemic immunomodulators, such as methotrexate or cyclosporine, provide broad anti-inflammatory control but require regular lab monitoring to manage risks of liver or kidney toxicity.

Clinicians often select phototherapy over systemic medications for pediatric patients, women who are pregnant or planning pregnancy (NB-UVB only), and individuals with underlying liver or kidney disease that prevents systemic drug use. BAD guidelines (Ling et al., 2016) emphasize that phototherapy serves as an important intermediate step before advancing patients to systemic biologics.

8. Pre-Treatment Phase

The pre-treatment phase includes a comprehensive clinical assessment, review of potential photosensitizing medications, baseline photo-testing, patient education, and establishment of individual radiation safety protocols.

During the initial consultation, a dermatologist documents the patient's medical history, prior light exposure, history of skin cancers, eye conditions, and detailed drug usage. Numerous standard medications induce photosensitivity, including thiazide diuretics, tetracycline antibiotics, fluoroquinolones, amiodarone, sulfonylureas, and non-steroidal anti-inflammatory drugs (NSAIDs). Patients must inform the team of any new prescription or over-the-counter medications introduced during phototherapy.

To establish safe starting radiation doses, clinicians perform formal phototesting:

• Minimal Erythema Dose (MED) Testing: Used prior to NB-UVB. A template with small exposure windows is applied to the patient's non-sun-exposed skin (typically the lower back). Increasing doses of UVB are delivered to each window. The skin is evaluated 24 hours later to identify the lowest radiation dose that produces uniform, clearly demarcated erythema (redness). The initial treatment dosage is set at 50% to 70% of the calculated MED.
• Minimal Phototoxic Dose (MPD) Testing: Used prior to oral PUVA. The patient ingests the prescribed dose of methoxsalen, and 1.5 to 2 hours later, small skin windows receive escalating UVA exposure. The skin is examined 48 hours later to determine the MPD, guiding the initial UVA starting dose.

When formal MED or MPD testing is unavailable, initial doses are selected conservatively using standard baseline tables calibrated to the patient's Fitzpatrick skin phototype (Types I through VI). Patients are educated on facial protection, genital shielding, consistent wearing of UV-blocking goggles, and the importance of avoiding natural sun exposure during their treatment course.

9. The Procedure — Step-by-Step Clinical Detail

Phototherapy is performed in specialized outpatient clinical settings under medical supervision. The procedure follows a standardized protocol to ensure safety, precise radiation delivery, and optimal clinical response.

Dosing protocols follow established escalation rules. For NB-UVB, treatments are administered 2 to 3 times weekly on non-consecutive days (e.g., Monday, Wednesday, Friday). Radiation dosages are increased by 10% to 20% each session, provided no unexpected erythema occurred from the previous dose. If mild asymptomatic erythema develops, the dose is held constant. If painful erythema or blistering occurs, treatment is paused until resolution and resumed at a 25% to 50% dose reduction (Ling et al., 2016).

10. Immediate Post-Procedure Period

The immediate post-procedure period spans the first 24 to 48 hours following a phototherapy session. During this window, clinicians monitor for acute cutaneous light reactions, manage transient side effects, and enforce post-treatment safety protocols.

Patients can resume normal routine activities immediately after leaving the phototherapy clinic. Unlike surgical procedures, phototherapy requires no physical rest period, systemic recovery time, or wound care. However, specific post-exposure guidelines must be followed to minimize complications:

• Emollient Application: Patients should apply liberal amounts of bland, fragrance-free moisturizing ointments or creams immediately after exposure to restore skin barrier hydration and counteract UV-induced dryness (xerosis).
• Sun Avoidance: Patients must avoid additional ambient natural sunlight or artificial tanning exposure on treatment days to prevent cumulative light toxicity and unexpected burning.
• Post-PUVA Eye Protection: Patients undergoing oral PUVA must wear wrap-around UVA-blocking sunglasses indoors and outdoors for 24 hours post-ingestion. Because methoxsalen distributes to the eye lens, light exposure during this period carries a risk of premature cataract formation.
• Erythema Monitoring: Peak erythema from NB-UVB typically appears 12 to 24 hours post-exposure. For PUVA, peak phototoxic erythema is delayed, appearing 48 to 72 hours post-treatment. Patients are instructed to report any persistent redness, burning sensations, or localized blistering prior to their next scheduled session.

11. Recovery — Short and Long Term

Recovery in phototherapy refers to progressive skin clearing and long-term disease remission. Response times vary based on the underlying diagnosis, skin phototype, and adherence to dosing schedules.

Short-Term Timeline (Weeks 1 to 4)

During the first 2 to 4 weeks (6 to 12 sessions), visible improvements are typically modest. Psoriatic plaques begin to show thinned scaling and decreased induration (thickness). In eczema, itching gradually subsides. Patients may experience mild transient redness or skin dryness, which is managed with emollients. In vitiligo, stabilization occurs, halting the spread of depigmented patches.

Intermediate Timeline (Weeks 5 to 12)

Between weeks 5 and 12 (15 to 36 sessions), therapeutic response accelerates. Clinical trials show that 60% to 75% of plaque psoriasis patients achieve 75% clearance (PASI 75) by session 20 to 24 under standard NB-UVB protocols (Elmets et al., 2019). In vitiligo, small macules of dark repigmentation appear around hair follicles within depigmented patches, gradually expanding and merging over 24 to 36 sessions.

Long-Term Remission and Tapering

Once clearance or maximum therapeutic gain is achieved (typically >90% clearance for psoriasis or stable repigmentation plateau for vitiligo), the dermatologist initiates a maintenance or tapering protocol. Dosing frequency is gradually reduced from 3 times weekly down to twice weekly, then once weekly, and finally discontinued over 4 to 8 weeks. Remission durations vary: psoriasis remissions average 6 to 12 months post-phototherapy, while vitiligo repigmentation often remains stable for years, provided underlying autoimmune activity stays controlled.

12. Risks, Side Effects, and Complications

While phototherapy is generally safe under clinical supervision, ultraviolet radiation poses predictable acute side effects and long-term risks, particularly with high cumulative lifetime exposures.

Long-Term Safety Data and Carcinogenesis

Long-term safety profiles differ significantly between NB-UVB and PUVA. Extensive cohort studies, including long-term registry data from the UK and Europe (Hearn et al., 2008), demonstrate that narrowband UVB phototherapy carries no significant increase in the incidence of non-melanoma skin cancer or melanoma, even in patients receiving over 300 sessions. NB-UVB is therefore considered exceptionally safe for repeated clinical courses.

In contrast, long-term prospective study data (Stern et al., 2012) confirm that high cumulative exposure to oral PUVA (>200 to 250 treatments) leads to a dose-dependent increase in non-melanoma skin cancer risk, particularly squamous cell carcinoma (SCC), with a smaller increase in basal cell carcinoma (BCC) and melanoma risk. The risk of SCC remains elevated years after discontinuing PUVA. Consequently, guidelines from the British Association of Dermatologists restrict lifetime PUVA exposures to a maximum threshold of 150 to 200 treatments per patient (Dawe et al., 2016).

13. Lifestyle and Behavioural Considerations

Patients undergoing phototherapy must make specific lifestyle adjustments to maintain treatment consistency, avoid accidental phototoxicity, and protect skin health throughout their care course.

Pre-Treatment Optimization

Patients should maintain hydrated, healthy skin by applying non-perfumed moisturizers daily. On treatment days, heavy ointments (such as petrolatum jelly or thick zinc oxide barrier creams) must not be applied immediately prior to entering the phototherapy unit unless instructed by the dermatologist. Heavy topical barriers reflect or absorb UV light unevenly, leading to inconsistent radiation delivery and localized disease shielding.

Medication and Cosmetic Precautions

• Avoid Scented Products: Perfumes, colognes, aftershaves, and scented body washes can contain essential oils (such as bergamot oil) that act as unexpected photosensitizers, causing patchy phototoxic burns.
• Avoid Tanning Beds and Uncontrolled Sun: Patients must not use commercial tanning beds or sunbathe while receiving phototherapy, as unpredictable light exposure significantly increases burning and skin cancer risks.
• Consistent Clothing Protocols: Patients who choose to wear underwear or partial clothing inside the cabinet must keep the exact same coverage lines across all treatment sessions. Exposing previously shielded, un-acclimated skin to higher radiation doses late in a protocol can cause severe local burns.

14. How Outcomes Are Measured

Dermatologists monitor phototherapy progress using validated clinical tools that evaluate disease extent, lesion severity, repigmentation metrics, and patient-reported quality of life.

Clinical Measurement Scales

• PASI (Psoriasis Area and Severity Index): Measures psoriasis extent and severity across four anatomical regions, tracking erythema, induration, and scaling on a scale of 0 to 72. PASI 75 (a 75% reduction from baseline) represents a standard benchmark for clinical treatment success.
• VASI (Vitiligo Area Scoring Index): Quantifies vitiligo depigmentation across body regions. Re-pigmenting progress is graded by evaluating the percentage of pigment restored within identified vitiligo macules over time.
• EASI (Eczema Area and Severity Index): Measures eczema severity, tracking redness, papulation, excoriation, and lichenification.
• DLQI (Dermatology Life Quality Index): A patient-completed 10-question survey measuring the practical impact of skin disease and treatment response on daily life, social interactions, and mental well-being.

Clearance Models and Repeat Courses

Phototherapy courses typically run for 12 to 16 weeks (30 to 48 treatments total). If a patient achieves complete or near-complete clearance, treatment is gradually tapered and discontinued. If disease recurs after several months or years, a repeat course of phototherapy can be considered. However, if a patient shows less than 50% clearance after 20 to 24 consistent sessions, the disease is deemed phototherapy-resistant, and clinicians transition the patient to alternative treatments such as systemic biologics or small-molecule inhibitors.

15. Recent Advances and Current Standard of Care

The standard of care for phototherapy has evolved over the past two decades, transitioning from broadband UVB and high-dose oral PUVA to targeted narrowband UVB (311 nm), home phototherapy models, and combination light-biologic protocols.

Key advancements shaping current clinical practice include:

• Narrowband UVB Dominance: High-rigor clinical studies have established NB-UVB (311–312 nm) as superior in safety and efficacy to historical broadband UVB. NB-UVB achieves clinical remissions faster with a lower incidence of acute phototoxic burns and no demonstrated skin cancer risk increase (Ling et al., 2016).
• Targeted 308-nm Excimer Delivery: The emergence of monochromatic 308-nanometer excimer lasers and high-intensity excimer light units allows dermatologists to deliver high-dose UV radiation exclusively to affected skin patches (e.g., localized vitiligo or resistant palmaplantar psoriasis) while completely sparing un-involved surrounding skin.
• Prescribed Home NB-UVB Units: For patients with mobility limitations or geographically remote access, prescription home NB-UVB cabinets equipped with integrated electronic lockouts and tele-dermatology oversight provide safe, effective clearance comparable to clinic-based systems (PLUTO Study, Koek et al., 2009).
• Combination Therapies: Modern standard-of-care protocols frequently combine low-dose phototherapy with topical vitamin D analogues (e.g., calcipotriene) or topical retinoids. Combining phototherapy with targeted systemic biologics is also being evaluated, allowing lower drug or light exposure while maintaining high clinical clearance rates.

16. Common Myths and Misconceptions

Myth: Medical phototherapy is identical to using a commercial tanning bed.
Reality: Commercial tanning beds emit high-intensity broad-spectrum UVA and unpredictable UVB designed for cosmetic tanning, which causes rapid skin aging and increases melanoma risk. Medical phototherapy utilizes precise, medically monitored wavelengths (311 nm NB-UVB or calibrated UVA) with strict dosage controls and safety shielding.

Myth: Phototherapy always causes skin cancer.
Reality: Extensive long-term cohort studies demonstrate that Narrowband UVB (NB-UVB) carries no significant increase in skin cancer risk, even over hundreds of treatments (Hearn et al., 2008). While high cumulative PUVA exposure (>200 treatments) does carry a non-melanoma skin cancer risk, lifetime limits and modern protocols minimize this hazard.

Myth: Phototherapy works after just one or two sessions.
Reality: Phototherapy relies on cumulative immunomodulatory effects that develop gradually over weeks. While itch relief may occur within days, visible clearance of psoriasis plaques or vitiligo repigmentation typically requires 15 to 30 consistent sessions over 2 to 3 months.

Myth: You must get a sunburn for phototherapy to be effective.
Reality: Erythema (sunburn) is an unwanted adverse effect, not a target endpoint. Medical light doses are carefully titrated just below the threshold of visible burning to achieve therapeutic suppression of immune cells without tissue damage.

Myth: Phototherapy cannot be used during pregnancy.
Reality: Narrowband UVB (NB-UVB) phototherapy involves zero systemic drug absorption and is explicitly recommended by AAD guidelines as a safe treatment for widespread psoriasis or eczema during pregnancy.

Myth: Vitiligo cannot be repigmented with light therapy.
Reality: NB-UVB phototherapy is the standard first-line therapy for stabilizing active vitiligo and stimulating follicular melanocyte stem cells to produce repigmentation, particularly on the face, trunk, and proximal limbs (Taieb et al., 2013).

17. Frequently Asked Questions

What is the main difference between NB-UVB and PUVA?

Narrowband UVB (NB-UVB) isolates a specific 311–312 nanometer wavelength and requires no drugs, making it the preferred first-line light therapy. PUVA combines UVA light (320–400 nanometers) with a photosensitizing medication (methoxsalen) taken orally or topically. PUVA penetrates deeper into the skin but carries greater long-term side-effect risks.

How many times a week do I need to attend phototherapy?

Phototherapy typically requires 2 to 3 sessions per week administered on non-consecutive days (such as Monday, Wednesday, and Friday). Consistency is critical; missed appointments delay therapeutic progress and may require dosage reductions to prevent skin burning upon resumption.

How long does a single phototherapy session take?

The light exposure itself is brief, lasting from 30 seconds to 15 minutes depending on your skin phototype and current dose stage. However, including disrobing, protective equipment positioning, and applying post-treatment moisturizers, a typical clinic visit takes approximately 15 to 20 minutes.

Can I receive phototherapy if I am pregnant?

Yes, narrowband UVB (NB-UVB) phototherapy is safe during pregnancy because it involves no systemic oral medications and does not penetrate beyond the superficial layers of the skin. Oral PUVA, however, is contraindicated during pregnancy due to potential fetal risks from methoxsalen.

Will phototherapy cause my skin to tan?

Yes, light exposure stimulates cutaneous melanocytes, leading to progressive tanning of normal skin surrounding your treatment areas. This localized pigment change is temporary and fades gradually after the phototherapy course is completed.

What happens if I miss several scheduled sessions?

If you miss treatments, your skin loses a portion of its light acclimation. Skipping several consecutive sessions requires the clinical team to step back your treatment dose to a lower radiation level to avoid acute burning upon your return.

Does phototherapy cure psoriasis or vitiligo permanently?

Phototherapy induces long-term disease remission but does not permanently cure underlying autoimmune skin conditions. Psoriasis remissions often last 6 to 12 months or longer, after which a repeat course or maintenance therapy may be considered.

Do I need to wear eye protection inside the light cabinet?

Yes, specialized UV-blocking safety goggles must be worn during every treatment session to prevent UV-induced corneal inflammation (photokeratitis) and lens damage. During oral PUVA, protective eyewear must also be worn outdoors for 24 hours post-ingestion.

Can children safely receive phototherapy?

Yes, narrowband UVB phototherapy is approved and safe for pediatric patients who can follow instructions and stand comfortably inside the light cabinet with safety goggles in place. Parents or nurses assist with positioning during sessions.

How soon will I see results for my skin condition?

Symptomatic itch relief often begins within 2 to 3 weeks. Visible thinning of psoriatic plaques or early vitiligo repigmentation typically becomes noticeable after 12 to 16 sessions (approximately 4 to 6 weeks of regular treatment).

What should I do if my skin turns bright red after a session?

If you experience significant redness, warm tenderness, or burning resembling a sunburn, apply cool compresses and bland emollients, and contact your dermatology clinic. Your clinician will pause or reduce your next radiation dose until the reaction resolves completely.

Can I apply my topical prescription ointments before light therapy?

No, you should not apply thick prescription ointments or moisturizers immediately before entering the light cabinet unless specifically directed by your doctor. Oils and barrier products can reflect light or cause uneven radiation absorption across your skin.